226 related articles for article (PubMed ID: 27881030)
1. The effect of tumor necrosis factor inhibitor therapy on the incidence of myocardial infarction in patients with psoriasis: a retrospective study.
Shaaban D; Al-Mutairi N
J Dermatolog Treat; 2018 Feb; 29(1):3-7. PubMed ID: 27881030
[TBL] [Abstract][Full Text] [Related]
2. Association between the type and length of tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.
Wu JJ; Poon KY; Bebchuk JD
J Drugs Dermatol; 2013 Aug; 12(8):899-903. PubMed ID: 23986163
[TBL] [Abstract][Full Text] [Related]
3. Do TNF inhibitors reduce the risk of myocardial infarction in psoriasis patients?
Armstrong AW
JAMA; 2013 May; 309(19):2043-4. PubMed ID: 23677316
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-α inhibitors versus methotrexate.
Wu JJ; Guérin A; Sundaram M; Dea K; Cloutier M; Mulani P
J Am Acad Dermatol; 2017 Jan; 76(1):81-90. PubMed ID: 27894789
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis.
Bissonnette R; Kerdel F; Naldi L; Papp K; Galindo C; Langholff W; Tang KL; Szapary P; Fakharzadeh S; Srivastava B; Goyal K; Gottlieb AB
J Drugs Dermatol; 2017 Oct; 16(10):1002-1013. PubMed ID: 29036254
[TBL] [Abstract][Full Text] [Related]
6. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB
J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
[TBL] [Abstract][Full Text] [Related]
7. Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis.
Gibellini L; De Biasi S; Bianchini E; Bartolomeo R; Fabiano A; Manfredini M; Ferrari F; Albertini G; Trenti T; Nasi M; Pinti M; Iannone A; Salvarani C; Cossarizza A; Pellacani G
PLoS One; 2016; 11(12):e0167757. PubMed ID: 27936119
[TBL] [Abstract][Full Text] [Related]
8. Anti-inflammatory therapy with tumour necrosis factor inhibitors is associated with reduced risk of major adverse cardiovascular events in psoriasis.
Wu JJ; Joshi AA; Reddy SP; Batech M; Egeberg A; Ahlehoff O; Mehta NN
J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1320-1326. PubMed ID: 29573294
[TBL] [Abstract][Full Text] [Related]
9. Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)-α level and the efficacy of TNF-inhibitor therapy in psoriasis.
Kui R; Gál B; Gaál M; Kiss M; Kemény L; Gyulai R
J Dermatol; 2016 Sep; 43(9):1018-23. PubMed ID: 26892625
[TBL] [Abstract][Full Text] [Related]
10. Initiation of TNF inhibitor therapy and change in physiologic measures in psoriasis.
Wu JJ; Liu L; Asgari MM; Curtis JR; Harrold L; Salman C; Herrinton LJ
J Eur Acad Dermatol Venereol; 2014 Oct; 28(10):1380-7. PubMed ID: 24708441
[TBL] [Abstract][Full Text] [Related]
11. Melanocytic nevus count and dermoscopic features do not differ in psoriatic patients undergoing biological agent versus conventional drug therapy.
Pirmit S; Onsun N; Su O; Ozkaya DB
G Ital Dermatol Venereol; 2017 Apr; 152(2):126-131. PubMed ID: 28166613
[TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis, psoriatic arthritis, or both.
Wu JJ; Poon KY
J Drugs Dermatol; 2014 Aug; 13(8):932-4. PubMed ID: 25116971
[TBL] [Abstract][Full Text] [Related]
13. Biologic drug survival in Israeli psoriasis patients.
Shalom G; Cohen AD; Ziv M; Eran CB; Feldhamer I; Freud T; Berman E; Oren S; Hodak E; Pavlovsky L
J Am Acad Dermatol; 2017 Apr; 76(4):662-669.e1. PubMed ID: 28038888
[TBL] [Abstract][Full Text] [Related]
14. Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: A patient series.
Lund T; Thomsen SF
Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28071837
[TBL] [Abstract][Full Text] [Related]
15. Anti-TNF agents and nail psoriasis: a single-center, retrospective, comparative study.
Kyriakou A; Patsatsi A; Sotiriadis D
J Dermatolog Treat; 2013 Jun; 24(3):162-8. PubMed ID: 22136334
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with tumor necrosis factor inhibitors in psoriasis treatment.
Famenini S; Wu JJ
Cutis; 2013 Sep; 92(3):140-7. PubMed ID: 24153143
[TBL] [Abstract][Full Text] [Related]
17. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
[TBL] [Abstract][Full Text] [Related]
18. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study.
Pugliese D; Guidi L; Ferraro PM; Marzo M; Felice C; Celleno L; Landi R; Andrisani G; Pizzolante F; De Vitis I; Papa A; Rapaccini GL; Armuzzi A
Aliment Pharmacol Ther; 2015 Oct; 42(7):880-8. PubMed ID: 26235565
[TBL] [Abstract][Full Text] [Related]
19. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.
Wu JJ; Poon KY; Channual JC; Shen AY
Arch Dermatol; 2012 Nov; 148(11):1244-50. PubMed ID: 22911151
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and efficacy of anti-tumor necrosis factor-alpha biosimilar agents in the treatment of psoriasis: a single center study.
Ricceri F; Rosi E; Di Cesare A; Scandagli I; Fastame MT; Prignano F
J Dermatolog Treat; 2022 Jun; 33(4):1983-1985. PubMed ID: 33929274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
